In-Silico Identification of Phytochemical Inhibitors of Mycobacterium tuberculosis Efflux Pumps: A Potential Strategy against Multidrug Resistance

سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 3

فایل این مقاله در 16 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IEM-12-1_004

تاریخ نمایه سازی: 1 تیر 1405

چکیده مقاله:

Background: Efflux pump-mediated antibiotic extrusion is a key mechanism of multidrug resistance in Mycobacterium tuberculosis (MTB). Inhibiting these pumps is a promising strategy for resensitizing resistant strains to conventional antibiotics.Materials & Methods: An integrated in silico approach was employed to evaluate the interaction of drug-like ligands, primarily phytochemicals, with key MTB efflux pumps. Homology models of DrrA, DrrB, and DrrC proteins and the crystal structure of Rv۱۸۱۹c were used for molecular docking. Top-scoring ligands were subsequently analyzed for drug-likeness, toxicity profile, and binding stability via molecular dynamics (MD) simulations to identify the most promising efflux pump inhibitors (EPIs).Findings: Molecular docking revealed high-affinity binding of several phytochemicals. The top-scoring ligands were curcumin, rosmarinic acid, and pracinostat for DrrA; curcumin, kanzonol C, and Skf-۱۰۰۳۳۰A for DrrB; and rosmarinic acid, curcumin, and kanzonol C for DrrC. For the Rv۱۸۱۹c protein, the top-scoring compounds were crocetin, curcumin, and kanzonol C, which were found to bind specifically to the ATP-interacting pocket. An integrated analysis of docking affinity, molecular dynamics stability, toxicity, and drug-likeness identified curcumin, kanzonol C, rosmarinic acid, and crocetin as the most promising candidate EPIs.Conclusion: The present in-silico study identified curcumin, kanzonol C, rosmarinic acid, and crocetin as promising phytochemical inhibitors of key MTB efflux pumps. These compounds exhibited potential for synergistic activity with conventional anti-tuberculosis drugs. Therefore, preclinical and experimental validation is warranted to confirm their efficacy as efflux pump inhibitors.

نویسندگان

Seyed Akbar Moosavi

Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Iran University of Medical Sciences and Health Services, Tehran, Iran

Abdorrahim Absalan

Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Iran University of Medical Sciences and Health Services, Tehran, Iran

Zahra Absalan

Department of Microbiology, Faculty of medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Fereshteh Parto

Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Iran University of Medical Sciences and Health Services, Tehran, Iran